OpenLB
Open Library of Bioscience
Advanced Search
NPJ vaccines
Jun 28, 2024;9 (1): 122.

Myocarditis associated with COVID-19 vaccination.

Alessandra Buoninfante, Arno Andeweg, Georgy Genov, Marco Cavaleri
Author Information
  1. Alessandra Buoninfante: Public Health Threats, European Medicines Agency, Amsterdam, The Netherlands. alessandra.buoninfante@ema.europa.eu. ORCID
  2. Arno Andeweg: Public Health Threats, European Medicines Agency, Amsterdam, The Netherlands. ORCID
  3. Georgy Genov: Pharmacovigilance Office, European Medicines Agency, Amsterdam, The Netherlands.
  4. Marco Cavaleri: Public Health Threats, European Medicines Agency, Amsterdam, The Netherlands. marco.cavaleri@ema.europa.eu. ORCID
PMID: 38942751 DOI: 10.1038/s41541-024-00893-1

Abstract

Following the start of the COVID-19 vaccination campaign, the adverse events of myocarditis and pericarditis were linked mainly to mRNA COVID-19 vaccines by the regulatory authorities worldwide. COVID-19 vaccines have been administered to several million people and the risk of myocarditis post COVID-19 vaccination has been characterised in great detail. At the present time the research data available are scarce and there is still no clear understanding of the biological mechanism/s responsible for this disease. This manuscript provides a concise overview of the epidemiology of myocarditis and the most prominent mechanistic insights in the pathophysiology of the disease. Most importantly it underscores the needed next steps in the research agenda required to characterize the pathophysiology of this disease post-COVID-19 vaccination. Finally, it shares our perspectives and considerations for public health.

References

  1. Nat Immunol. 2022 Apr;23(4):532-542 [PMID: 35332327]
  2. Int J Infect Dis. 2023 Jun;131:75-78 [PMID: 36967038]
  3. Nature. 2021 Aug;596(7872):410-416 [PMID: 34252919]
  4. Nat Commun. 2022 Jun 25;13(1):3633 [PMID: 35752614]
  5. Nat Commun. 2023 Apr 3;14(1):1845 [PMID: 37012238]
  6. Circulation. 2023 Mar 14;147(11):867-876 [PMID: 36597886]
  7. N Engl J Med. 2021 Sep 30;385(14):1332-1334 [PMID: 34407340]
  8. JAMA Netw Open. 2022 Jun 1;5(6):e2218505 [PMID: 35749115]
  9. Clin Immunol. 1999 Jan;90(1):15-21 [PMID: 9884348]
  10. Redox Biol. 2020 Apr;31:101482 [PMID: 32197947]
  11. Vaccine. 2022 Jul 30;40(32):4394-4402 [PMID: 35667917]
  12. Nat Rev Cardiol. 2021 Mar;18(3):169-193 [PMID: 33046850]
  13. Front Immunol. 2022 Feb 18;13:851620 [PMID: 35251049]
  14. Am J Prev Med. 2023 Feb;64(2):275-284 [PMID: 36266115]
  15. Circulation. 2022 Sep 6;146(10):743-754 [PMID: 35993236]
  16. Nat Med. 2022 Feb;28(2):410-422 [PMID: 34907393]
  17. Lancet Rheumatol. 2022 May;4(5):e329-e337 [PMID: 35368387]
  18. Lancet Respir Med. 2022 Jul;10(7):679-688 [PMID: 35421376]
  19. Front Pharmacol. 2022 Nov 24;13:1038043 [PMID: 36506571]
  20. J Immunol. 2007 Jun 1;178(11):6710-4 [PMID: 17513715]
  21. Clin Res Cardiol. 2023 Mar;112(3):431-440 [PMID: 36436002]
  22. N Engl J Med. 2021 Dec 2;385(23):2140-2149 [PMID: 34614328]
  23. BMJ Med. 2023 Feb 1;2(1):e000373 [PMID: 36936260]
  24. BMJ. 2022 Jul 13;378:e069445 [PMID: 35830976]
  25. EBioMedicine. 2022 Jan;75:103807 [PMID: 34998242]
  26. Mol Cells. 2022 Oct 31;45(10):738-748 [PMID: 35904026]
  27. Front Cardiovasc Med. 2019 May 16;6:64 [PMID: 31157241]
  28. CMAJ. 2022 Nov 21;194(45):E1529-E1536 [PMID: 36410749]
  29. J Clin Immunol. 2022 Oct;42(7):1354-1359 [PMID: 36207567]
  30. Clin Sci (Lond). 2021 Dec 22;135(24):2667-2689 [PMID: 34807265]
  31. HGG Adv. 2022 Apr 14;3(2):100084 [PMID: 35005651]
  32. Cell. 2022 Mar 17;185(6):1025-1040.e14 [PMID: 35148837]
  33. J Am Coll Cardiol. 2022 Dec 13;80(24):2255-2265 [PMID: 36480967]
  34. Sci Immunol. 2023 May 12;8(83):eadh3455 [PMID: 37146127]
  35. Clin Pharmacol Ther. 2023 Jun;113(6):1223-1234 [PMID: 36524423]
  36. PLoS Med. 2023 Jun 7;20(6):e1004245 [PMID: 37285378]
  37. J Biol Chem. 2022 Mar;298(3):101695 [PMID: 35143839]
  38. N Engl J Med. 2022 Oct 20;387(16):1524-1527 [PMID: 36130012]
  39. JAMA. 2003 Jun 25;289(24):3283-9 [PMID: 12824210]
  40. Expert Rev Vaccines. 2023 Jan-Dec;22(1):25-34 [PMID: 36413786]
  41. MMWR Morb Mortal Wkly Rep. 2021 Sep 03;70(35):1228-1232 [PMID: 34473684]
  42. Clin Exp Immunol. 2012 Aug;169(2):79-88 [PMID: 22774982]
  43. J Am Heart Assoc. 2019 Jan 22;8(2):e008968 [PMID: 30638108]
  44. N Engl J Med. 2021 Sep 16;385(12):1078-1090 [PMID: 34432976]
  45. Nat Rev Cardiol. 2022 Feb;19(2):75-77 [PMID: 34887571]
  46. Clin Infect Dis. 2022 Jun 10;74(11):1933-1950 [PMID: 34406358]
  47. MMWR Morb Mortal Wkly Rep. 2022 Sep 02;71(35):1115-1120 [PMID: 36048728]
  48. Sci Rep. 2023 Jun 1;13(1):8926 [PMID: 37264110]
  49. JAMA Cardiol. 2022 Jun 1;7(6):600-612 [PMID: 35442390]
  50. Lancet Child Adolesc Health. 2022 Nov;6(11):788-798 [PMID: 36152650]
  51. Immunity. 2022 Nov 8;55(11):1993-2005 [PMID: 36351374]
  52. Pathogens. 2022 Jun 29;11(7): [PMID: 35889989]
  53. Heart. 2013 Nov;99(22):1681-4 [PMID: 24064227]
  54. Nat Commun. 2023 Mar 9;14(1):1299 [PMID: 36894554]
  55. JAMA Pediatr. 2023 Apr 1;177(4):410-418 [PMID: 36848096]
  56. J Cardiovasc Transl Res. 2014 Mar;7(2):192-202 [PMID: 24402571]
  57. JAMA. 2023 Apr 4;329(13):1098-1113 [PMID: 37014337]
  58. Clin Infect Dis. 2022 Mar 1;74(4):715-718 [PMID: 34015087]
Journal Article Review
Article has an altmetric score of 485

Word Cloud

Created with Highcharts 10.0.0COVID-19vaccinationmyocarditisdiseasevaccinesresearchpathophysiologyFollowingstartcampaignadverseeventspericarditislinkedmainlymRNAregulatoryauthoritiesworldwideadministeredseveralmillionpeopleriskpostcharacterisedgreatdetailpresenttimedataavailablescarcestillclearunderstandingbiologicalmechanism/sresponsiblemanuscriptprovidesconciseoverviewepidemiologyprominentmechanisticinsightsimportantlyunderscoresneedednextstepsagendarequiredcharacterizepost-COVID-19FinallysharesperspectivesconsiderationspublichealthMyocarditisassociated

Similar Articles

Cited By